{"id":28150,"date":"2026-03-09T11:28:02","date_gmt":"2026-03-09T11:28:02","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/28150\/"},"modified":"2026-03-09T11:28:02","modified_gmt":"2026-03-09T11:28:02","slug":"roches-cancer-drug-setback-stocks-tumble","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/28150\/","title":{"rendered":"Roche&#8217;s Cancer Drug Setback: Stocks Tumble"},"content":{"rendered":"<p>&#13;<\/p>\n<p>Roche&#8217;s stocks took a hit on Monday, dropping over 5%, as their breast cancer drug candidate, giredestrant, did not meet expectations in its recent trial. <\/p>\n<p>The stock saw a modest recovery during the morning, trading down 4.6% to 325.80 Swiss francs, marking a two-month low. The late-stage trial failed to demonstrate that giredestrant, in combination with Pfizer&#8217;s Ibrance, was more effective than standard hormonal therapies.<\/p>\n<p>Despite the setback, analysts perceive potential. Barclays&#8217; James Gordon suggests the share drop presents a buying opportunity, with market opportunities for add-on treatments not fully realized. However, Jefferies analyst Michael Leuchten anticipates the news will reverse previous positive momentum.<\/p>\n<p>&#13;<\/p>\n<p>(With inputs from agencies.)<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; Roche&#8217;s stocks took a hit on Monday, dropping over 5%, as their breast cancer drug candidate, giredestrant,&hellip;\n","protected":false},"author":2,"featured_media":28151,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[207,4067,17051,3517,250,265,304,134,2220,1424],"class_list":{"0":"post-28150","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-breast-cancer","9":"tag-clinical-trial","10":"tag-drug-trial","11":"tag-giredestrant","12":"tag-investment","13":"tag-oncology","14":"tag-pharmaceutical","15":"tag-roche","16":"tag-shares","17":"tag-stock-market"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116198985088258274","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/28150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=28150"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/28150\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/28151"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=28150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=28150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=28150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}